Dextroamphetamine saccharate 1.25 mg / amphetamine aspartate 1.25 mg / dextroamphetamine sulfate 1.25 mg / amphetamine sulfate 1.25 mg 24HR Extended Release Oral Capsule
RxNorm 861237

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 861237 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: dextroamphetamine saccharate 1.25 mg / amphetamine aspartate 1.25 mg / dextroamphetamine sulfate 1.25 mg / amphetamine sulfate 1.25 mg 24HR Extended Release Oral Capsule.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
24 HR amphetamine aspartate 1.25 mg / amphetamine sulfate 1.25 mg / dextroamphetamine saccharate 1.25 mg / dextroamphetamine sulfate 1.25 mg Extended Release Oral Capsule
Primary clinical definition
AUI:12348302
View
SY
Amphetamine aspartate 1.25 mg / amphetamine sulfate 1.25 mg / dextroamphetamine saccharate 1.25 mg / dextroamphetamine sulfate 1.25 mg 24 HR Extended Release Oral Capsule
AUI:6356576
View
PSN
Dextroamphetamine saccharate 1.25 mg / amphetamine aspartate 1.25 mg / dextroamphetamine sulfate 1.25 mg / amphetamine sulfate 1.25 mg 24HR Extended Release Oral Capsule
AUI:6366391
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDPrescribable

Semantic Clinical Drug (SCD):
24 HR amphetamine aspartate 1.25 mg / amphetamine sulfate 1.25 mg / dextroamphetamine saccharate 1.25 mg / dextroamphetamine sulfate 1.25 mg Extended Release Oral Capsule
(Atom ID: 12348302)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
24 HR amphetamine aspartate 1.25 MG / amphetamine sulfate 1.25 MG / dextroamphetamine saccharate 1.25 MG / dextroamphetamine sulfate 1.25 MG Extended Release Oral Capsule
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
861237
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12348302
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
861237
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260504F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{540473} 221057
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{540474} 81952
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{540476} 221088
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{578551} 3287
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{540473} 725
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{540474} 725
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{540476} 3288
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{578551} 3288
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
1.25 MG / 1.25 MG / 1.25 MG / 1.25 MG
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{540473} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{540474} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{540476} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{578551} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
RXN QUANTITY
24 HR
Normal Form quantity factor
SYPrescribable

Synonym (SY):
Amphetamine aspartate 1.25 mg / amphetamine sulfate 1.25 mg / dextroamphetamine saccharate 1.25 mg / dextroamphetamine sulfate 1.25 mg 24 HR Extended Release Oral Capsule
(Atom ID: 6356576)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
amphetamine aspartate 1.25 MG / amphetamine sulfate 1.25 MG / dextroamphetamine saccharate 1.25 MG / dextroamphetamine sulfate 1.25 MG 24 HR Extended Release Oral Capsule
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
861237
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6356576
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
861237
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260504F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
PSNPrescribable

Prescribable Name (PSN):
Dextroamphetamine saccharate 1.25 mg / amphetamine aspartate 1.25 mg / dextroamphetamine sulfate 1.25 mg / amphetamine sulfate 1.25 mg 24HR Extended Release Oral Capsule
(Atom ID: 6366391)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
dextroamphetamine saccharate 1.25 MG / amphetamine aspartate 1.25 MG / dextroamphetamine sulfate 1.25 MG / amphetamine sulfate 1.25 MG 24HR Extended Release Oral Capsule
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
861237
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6366391
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
861237
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260504F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Dextroamphetamine and Amphetamine


The combination of dextroamphetamine and amphetamine (Adderall, Adderall XR, Mydayis) is used as part of a treatment program to control symptoms of attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet than other people who are the same age). Adderall is used to treat ADHD in adults and children 3 years of age and older. Adderall XR is used to treat ADHD in adults and children 6 years of age and older. Mydayis is used to treat ADHD in adults and children 13 years of age and older. Dextroamphetamine and amphetamine (Adderall) is also used to treat narcolepsy (a sleep disorder that causes excessive daytime sleepiness and sudden attacks of sleep) in adults and children 12 years of age and older. The combination of dextroamphetamine and amphetamine is in a class of medications called central nervous system stimulants. It works by changing the amounts of certain natural substances in the brain.
[Learn More]


* Please review the disclaimer below.